Pharmacokinetics and pharmacodynamics of ponesimod, a selective <scp>S1P<sub>1</sub></scp> receptor modulator, in the first‐in‐human study
Patrick Brossard(Actelion (Switzerland)), Jasper Dingemanse(Actelion (Switzerland)), Haidar Maatouk(Clinical Research Services), Jian Xu(University of California, Los Angeles), Hartmut Derendorf(University of Florida), Atef Halabi(Pharmalog (Germany))
Cited by 111
Related Papers
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice
|Diabetes|2018|385
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
Protein Binding: Do We Ever Learn?
|Antimicrobial Agents and Chemotherapy|2011|247